Nilo Therapeutics
4 known investors
Find your way into Nilo Therapeutics
Nilo Therapeutics develops immunomodulation therapies that target brain-body neural circuits controlling systemic inflammation, aiming to treat autoimmune and inflammatory diseases. Its approach is focused on restoring immune homeostasis in conditions with large unmet medical need.
Founders & leadership
KS
Kim SethinCEO
Investors · 4
The Column GroupSan Francisco · $30M
DCVC Bioreported · 2 sourcesPalo Alto
Lux Capitalreported · 2 sourcesNew York · $100K – $100M
Also in the syndicate · 1
Gates Foundation
Funding
SEC filings, press & company announcements$101M disclosed across 1 round · 2025
- $101MSeries AOct 2025 · 5 sources
DCVC Bio (lead), Lux Capital (lead), The Column Group (lead), Alexandria Venture Investments, Gates Foundation
Source ↗
Source: company announcements and press reports — follow each round's link for the claim.
In the news
Frequently asked questions
- What does Nilo Therapeutics do?
- Nilo Therapeutics develops immunomodulation therapies that target brain-body neural circuits controlling systemic inflammation, aiming to treat autoimmune and inflammatory diseases. Its approach is focused on restoring immune homeostasis in conditions with large unmet medical need.
- Who are Nilo Therapeutics's investors?
- Nilo Therapeutics's investors include The Column Group, DCVC Bio, Lux Capital.
- How much funding has Nilo Therapeutics raised?
- Nilo Therapeutics has disclosed $101M raised across 1 round.